241 related articles for article (PubMed ID: 21159611)
1. Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.
Bohndiek SE; Kettunen MI; Hu DE; Witney TH; Kennedy BW; Gallagher FA; Brindle KM
Mol Cancer Ther; 2010 Dec; 9(12):3278-88. PubMed ID: 21159611
[TBL] [Abstract][Full Text] [Related]
2. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.
Bohndiek SE; Kettunen MI; Hu DE; Brindle KM
Cancer Res; 2012 Feb; 72(4):854-64. PubMed ID: 22223844
[TBL] [Abstract][Full Text] [Related]
3. The potential of hyperpolarized
Iversen AB; Busk M; Bertelsen LB; Laustsen C; Munk OL; Nielsen T; Wittenborn TR; Bussink J; Lok J; Stødkilde-Jørgensen H; Horsman MR
Acta Oncol; 2017 Nov; 56(11):1626-1633. PubMed ID: 28840759
[TBL] [Abstract][Full Text] [Related]
4. Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.
Mignion L; Dutta P; Martinez GV; Foroutan P; Gillies RJ; Jordan BF
Cancer Res; 2014 Feb; 74(3):686-94. PubMed ID: 24285723
[TBL] [Abstract][Full Text] [Related]
5. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
6. Direct arterial injection of hyperpolarized
Reynolds S; Metcalf S; Cochrane EJ; Collins RC; Jones S; Paley MNJ; Tozer GM
Magn Reson Med; 2017 Dec; 78(6):2116-2126. PubMed ID: 28191664
[TBL] [Abstract][Full Text] [Related]
7. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
8. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
10. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
11. Hyperpolarized [1,4-
Miller JJ; Lau AZ; Nielsen PM; McMullen-Klein G; Lewis AJ; Jespersen NR; Ball V; Gallagher FA; Carr CA; Laustsen C; Bøtker HE; Tyler DJ; Schroeder MA
JACC Cardiovasc Imaging; 2018 Nov; 11(11):1594-1606. PubMed ID: 29248653
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
Salmon BA; Salmon HW; Siemann DW
Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
[TBL] [Abstract][Full Text] [Related]
13. Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopy.
Witney TH; Brindle KM
Biochem Soc Trans; 2010 Oct; 38(5):1220-4. PubMed ID: 20863288
[TBL] [Abstract][Full Text] [Related]
14. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.
Shao H; Ni Y; Zhang J; Chen F; Dai X; Fan G; Sun Z; Xu K
PLoS One; 2013; 8(12):e82649. PubMed ID: 24376560
[TBL] [Abstract][Full Text] [Related]
18. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.
Gallagher FA; Kettunen MI; Hu DE; Jensen PR; Zandt RI; Karlsson M; Gisselsson A; Nelson SK; Witney TH; Bohndiek SE; Hansson G; Peitersen T; Lerche MH; Brindle KM
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19801-6. PubMed ID: 19903889
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
